A comparison of center-based vs. home-based daily hemodialysis for patients with end-stage renal disease

Michael Kraus, John Burkart, Rebecca Hegeman, Richard Solomon, Norman Coplon, John Moran

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Home hemodialysis has been a therapeutic option for almost 4 decades. The complexity of dialysis equipment has been a factor-limiting adoption of this modality. We performed a feasibility study to demonstrate the safety of center-based vs. home-based daily hemodialysis with the NxStage System One portable hemodialysis device. We also performed a retrospective analysis to determine if clinical effects previously associated with short-daily dialysis were also seen using this novel device. We conducted a prospective, 2-treatment, 2-period, open-label, crossover study of in-center hemodialysis vs. home hemodialysis in 32 patients treated at 6 U.S. centers. The 8-week In-Center Phase (6 days/ week) was followed by a 2-week transition period and then followed by the 8-week Home Phase (6 days/week). We retrospectively collected data on hemodialysis treatment parameters immediately preceding the study in a subset of patients. Twenty-six out of 32 patients (81%) successfully completed the study. Successful delivery of at least 90% of prescribed fluid volume (primary endpoint) was achieved in 98.5% of treatments in-center and 97.3% at home. Total effluent volume as a percentage of prescribed volume was between 94% and 100% for all study weeks. The composite rate of intradialytic and interdialytic adverse events per 100 treatments was significantly higher for the In-Center Phase (5.30) compared with the Home Phase (2.10; p = 0.007). Compared with the period immediately preceding the study, there were reductions in blood pressure, antihypertensive medications, and interdialytic weight gain. Daily home hemodialysis with a small, easy-to-use hemodialysis device is a viable dialysis option for end-stage renal disease patients capable of self/partner-administered dialysis.

Original languageEnglish
Pages (from-to)468-477
Number of pages10
JournalHemodialysis International
Volume11
Issue number4
DOIs
StatePublished - Oct 2007

Fingerprint

Home Hemodialysis
Chronic Kidney Failure
Renal Dialysis
Dialysis
Equipment and Supplies
Therapeutics
Feasibility Studies
Cross-Over Studies
Antihypertensive Agents
Weight Gain
Blood Pressure
Safety

Keywords

  • Daily hemodialysis
  • End-stage renal disease
  • ESRD
  • Hemodialysis
  • Hospitalization

ASJC Scopus subject areas

  • Hematology

Cite this

A comparison of center-based vs. home-based daily hemodialysis for patients with end-stage renal disease. / Kraus, Michael; Burkart, John; Hegeman, Rebecca; Solomon, Richard; Coplon, Norman; Moran, John.

In: Hemodialysis International, Vol. 11, No. 4, 10.2007, p. 468-477.

Research output: Contribution to journalArticle

Kraus, Michael ; Burkart, John ; Hegeman, Rebecca ; Solomon, Richard ; Coplon, Norman ; Moran, John. / A comparison of center-based vs. home-based daily hemodialysis for patients with end-stage renal disease. In: Hemodialysis International. 2007 ; Vol. 11, No. 4. pp. 468-477.
@article{800d89a9af11478faa7f7e509eef5d19,
title = "A comparison of center-based vs. home-based daily hemodialysis for patients with end-stage renal disease",
abstract = "Home hemodialysis has been a therapeutic option for almost 4 decades. The complexity of dialysis equipment has been a factor-limiting adoption of this modality. We performed a feasibility study to demonstrate the safety of center-based vs. home-based daily hemodialysis with the NxStage System One portable hemodialysis device. We also performed a retrospective analysis to determine if clinical effects previously associated with short-daily dialysis were also seen using this novel device. We conducted a prospective, 2-treatment, 2-period, open-label, crossover study of in-center hemodialysis vs. home hemodialysis in 32 patients treated at 6 U.S. centers. The 8-week In-Center Phase (6 days/ week) was followed by a 2-week transition period and then followed by the 8-week Home Phase (6 days/week). We retrospectively collected data on hemodialysis treatment parameters immediately preceding the study in a subset of patients. Twenty-six out of 32 patients (81{\%}) successfully completed the study. Successful delivery of at least 90{\%} of prescribed fluid volume (primary endpoint) was achieved in 98.5{\%} of treatments in-center and 97.3{\%} at home. Total effluent volume as a percentage of prescribed volume was between 94{\%} and 100{\%} for all study weeks. The composite rate of intradialytic and interdialytic adverse events per 100 treatments was significantly higher for the In-Center Phase (5.30) compared with the Home Phase (2.10; p = 0.007). Compared with the period immediately preceding the study, there were reductions in blood pressure, antihypertensive medications, and interdialytic weight gain. Daily home hemodialysis with a small, easy-to-use hemodialysis device is a viable dialysis option for end-stage renal disease patients capable of self/partner-administered dialysis.",
keywords = "Daily hemodialysis, End-stage renal disease, ESRD, Hemodialysis, Hospitalization",
author = "Michael Kraus and John Burkart and Rebecca Hegeman and Richard Solomon and Norman Coplon and John Moran",
year = "2007",
month = "10",
doi = "10.1111/j.1542-4758.2007.00229.x",
language = "English",
volume = "11",
pages = "468--477",
journal = "Hemodialysis International",
issn = "1492-7535",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - A comparison of center-based vs. home-based daily hemodialysis for patients with end-stage renal disease

AU - Kraus, Michael

AU - Burkart, John

AU - Hegeman, Rebecca

AU - Solomon, Richard

AU - Coplon, Norman

AU - Moran, John

PY - 2007/10

Y1 - 2007/10

N2 - Home hemodialysis has been a therapeutic option for almost 4 decades. The complexity of dialysis equipment has been a factor-limiting adoption of this modality. We performed a feasibility study to demonstrate the safety of center-based vs. home-based daily hemodialysis with the NxStage System One portable hemodialysis device. We also performed a retrospective analysis to determine if clinical effects previously associated with short-daily dialysis were also seen using this novel device. We conducted a prospective, 2-treatment, 2-period, open-label, crossover study of in-center hemodialysis vs. home hemodialysis in 32 patients treated at 6 U.S. centers. The 8-week In-Center Phase (6 days/ week) was followed by a 2-week transition period and then followed by the 8-week Home Phase (6 days/week). We retrospectively collected data on hemodialysis treatment parameters immediately preceding the study in a subset of patients. Twenty-six out of 32 patients (81%) successfully completed the study. Successful delivery of at least 90% of prescribed fluid volume (primary endpoint) was achieved in 98.5% of treatments in-center and 97.3% at home. Total effluent volume as a percentage of prescribed volume was between 94% and 100% for all study weeks. The composite rate of intradialytic and interdialytic adverse events per 100 treatments was significantly higher for the In-Center Phase (5.30) compared with the Home Phase (2.10; p = 0.007). Compared with the period immediately preceding the study, there were reductions in blood pressure, antihypertensive medications, and interdialytic weight gain. Daily home hemodialysis with a small, easy-to-use hemodialysis device is a viable dialysis option for end-stage renal disease patients capable of self/partner-administered dialysis.

AB - Home hemodialysis has been a therapeutic option for almost 4 decades. The complexity of dialysis equipment has been a factor-limiting adoption of this modality. We performed a feasibility study to demonstrate the safety of center-based vs. home-based daily hemodialysis with the NxStage System One portable hemodialysis device. We also performed a retrospective analysis to determine if clinical effects previously associated with short-daily dialysis were also seen using this novel device. We conducted a prospective, 2-treatment, 2-period, open-label, crossover study of in-center hemodialysis vs. home hemodialysis in 32 patients treated at 6 U.S. centers. The 8-week In-Center Phase (6 days/ week) was followed by a 2-week transition period and then followed by the 8-week Home Phase (6 days/week). We retrospectively collected data on hemodialysis treatment parameters immediately preceding the study in a subset of patients. Twenty-six out of 32 patients (81%) successfully completed the study. Successful delivery of at least 90% of prescribed fluid volume (primary endpoint) was achieved in 98.5% of treatments in-center and 97.3% at home. Total effluent volume as a percentage of prescribed volume was between 94% and 100% for all study weeks. The composite rate of intradialytic and interdialytic adverse events per 100 treatments was significantly higher for the In-Center Phase (5.30) compared with the Home Phase (2.10; p = 0.007). Compared with the period immediately preceding the study, there were reductions in blood pressure, antihypertensive medications, and interdialytic weight gain. Daily home hemodialysis with a small, easy-to-use hemodialysis device is a viable dialysis option for end-stage renal disease patients capable of self/partner-administered dialysis.

KW - Daily hemodialysis

KW - End-stage renal disease

KW - ESRD

KW - Hemodialysis

KW - Hospitalization

UR - http://www.scopus.com/inward/record.url?scp=35148827030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35148827030&partnerID=8YFLogxK

U2 - 10.1111/j.1542-4758.2007.00229.x

DO - 10.1111/j.1542-4758.2007.00229.x

M3 - Article

C2 - 17922746

AN - SCOPUS:35148827030

VL - 11

SP - 468

EP - 477

JO - Hemodialysis International

JF - Hemodialysis International

SN - 1492-7535

IS - 4

ER -